Melinta Therapeutics, Inc. is a Morristown, New Jersey-based biopharmaceutical company focused on the development and commercialization of antibiotics for serious bacterial infections. The company’s portfolio includes four FDA-approved medications: Baxdela, Vabomere, Orbactiv, and Minocin for injection. Melinta operates through a model utilizing third-party contract manufacturers for production and maintains commercial partnerships for distribution in Europe, Asia-Pacific, and Latin America. The company is publicly traded on the Nasdaq under the ticker MLNT.